Form 4: Fate Therapeutics Director Karin Jooss Granted 55,000 Stock Options Under Compensation Policy

Fate Therapeutics, Inc. Director Karin Jooss was granted 55,000 stock options with an exercise price of $1.32, vesting on May 29, 2026, or the 2026 Annual Meeting, as part of the company's non-employee director compensation policy.

Summary

• Karin Jooss, a Director of Fate Therapeutics, Inc. (FATE), was granted 55,000 stock options on May 29, 2025.
• The options have an exercise price of $1.32 per share and will expire on May 29, 2035.
• The shares subject to this option grant will vest and become exercisable on the earlier of May 29, 2026, or the date of Fate Therapeutics' 2026 Annual Meeting of Stockholders.
• Vesting is contingent upon Ms. Jooss's continued service on the Issuer's Board of Directors.
• This grant is part of the company's Amended and Restated Non-Employee Director Compensation Policy, which provides for annual equity grants to non-employee directors.

Sentiment

Score: 7

Explanation: The document reports a routine stock option grant to a director as part of a compensation policy. This is generally positive for aligning director incentives with shareholder interests and retaining talent, without indicating any negative operational or financial news for the company itself. The grant is an expected part of compensation.

Positives

• The grant of 55,000 stock options to Director Karin Jooss aligns her interests with shareholders by providing an incentive for long-term company performance.
• The options were granted at an exercise price of $1.32, which could represent future upside potential if the stock price increases.
• The grant is part of a pre-existing, disclosed compensation policy, indicating a structured approach to director remuneration.

Negatives

• The issuance of new stock options can lead to potential future dilution for existing shareholders if the options are exercised.

Risks

• The value of the stock options is dependent on the future performance of Fate Therapeutics' stock price; if the stock price does not exceed the exercise price, the options may not be valuable.
• The vesting of the options is subject to Karin Jooss's continued service on the Board of Directors, meaning the benefit is contingent on her ongoing role.

Future Outlook

The granted stock options are set to vest on the earlier of May 29, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, provided the reporting person continues her service on the Board. The options have an expiration date of May 29, 2035, indicating a long-term incentive.

Management Comments

• "This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders."
• "The shares subject to this option shall vest and become exercisable on the earlier of (i) May 29, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."

Industry Context

This is a routine insider transaction filing (Form 4) detailing an equity compensation grant to a director. Such grants are common practice across industries, including biotechnology, to align director incentives with shareholder value. It does not provide broader industry trends or competitive insights.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard practice in publicly traded companies, particularly in the biotechnology sector, to attract and retain qualified board members.
• The vesting schedule, tied to continued service and an annual meeting, is typical for such compensation arrangements.
• The exercise price being set at a specific value ($1.32) is standard for option grants.

Corporate Governance

Related Party Transactions

• The grant of 55,000 stock options to Karin Jooss, a director of Fate Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefits from aligning director incentives with long-term company performance and retention of experienced board members.
• Employees: No direct impact mentioned, but reflects the company's overall compensation philosophy for key personnel.
• Directors: Karin Jooss directly benefits from the equity grant, providing a financial incentive tied to the company's stock performance.

Next Steps

• Vesting of 55,000 stock options on the earlier of May 29, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.
• Potential exercise of options by Karin Jooss after vesting and before the expiration date of May 29, 2035.

Key Dates

Keywords

Fate Therapeutics, FATE, Stock Option Grant, Director Compensation, SEC Form 4, Insider Transaction, Equity Compensation, Karin Jooss, Biotechnology, Pharmaceuticals